Literature DB >> 6469346

Protection of mice against Vibrio vulnificus disease by vaccination with surface antigen preparations and anti-surface antigen antisera.

A S Kreger, L D Gray, J Testa.   

Abstract

Vaccination of mice with either Formalin-killed cells or cell extracts of a virulent strain and a weakly virulent strain of Vibrio vulnificus or with rabbit antisera (AS) against the Formalin-killed cells and cell extracts protected against the virulent strain of V. vulnificus. However, the virulent strain vaccines and AS elicited a significantly stronger immune response than the weakly virulent strain vaccines and AS. Adsorption of the AS with either the homologous or heterologous Formalin-killed cells significantly reduced the ability of the AS to protect mice. The major protective antigen(s) in the cell extracts migrated in the void volume of Sephacryl S-400 superfine, was not effectively sedimented by centrifugation at 100,000 X g for 2 h, had an isoelectric point of 3.8 to 4.2, and was sensitive to boiling or autoclaving for 15 min, periodate oxidation, and exposure to pH 12 but was resistant to 56 degrees C, trypsin, pronase, RNase, neuraminidase, and pH 4.5. Electron microscopy revealed that the virulent strain possessed a more dense ruthenium red-staining layer on its outer membrane and had a much smoother surface than the weakly virulent strain. Our results provide evidence that a major protective antigen and virulence factor of V. vulnificus is a heat-labile, acidic polysaccharide located on the bacterial surface.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6469346      PMCID: PMC263326          DOI: 10.1128/iai.45.3.537-543.1984

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

1.  Halophilic, lactose-positive Vibrio in a case of fatal septicemia.

Authors:  A Mertens; J Nagler; W Hansen; E Gepts-Friedenreich
Journal:  J Clin Microbiol       Date:  1979-02       Impact factor: 5.948

2.  PERIODATE OXIDATION OF THE GLYCOPROTEIN FETUIN.

Authors:  R G SPIRO
Journal:  J Biol Chem       Date:  1964-02       Impact factor: 5.157

Review 3.  Diseases of humans (other than cholera) caused by vibrios.

Authors:  P A Blake; R E Weaver; D G Hollis
Journal:  Annu Rev Microbiol       Date:  1980       Impact factor: 15.500

4.  Halophilic Vibrio sepsis.

Authors:  D B Craig; D L Stevens
Journal:  South Med J       Date:  1980-09       Impact factor: 0.954

5.  Fulminating lactose-positive Vibrio septicemia.

Authors:  T Matsuo; S Kohno; T Ikeda; K Saruwatari; H Ninomiya
Journal:  Acta Pathol Jpn       Date:  1978-11

6.  Vibrio ("Beneckea") vulnificus, the bacterium associated with sepsis, septicaemia, and the sea.

Authors:  J J Farmer
Journal:  Lancet       Date:  1979-10-27       Impact factor: 79.321

7.  Halophilic Vibrio species isolated from blood cultures.

Authors:  D G Hollis; R E Weaver; C N Baker; C Thornsberry
Journal:  J Clin Microbiol       Date:  1976-04       Impact factor: 5.948

8.  Experimental pathogenicity and mortality in ligated ileal loop studies of the newly reported halophilic lactose-positive Vibrio sp.

Authors:  M D Poole; J D Oliver
Journal:  Infect Immun       Date:  1978-04       Impact factor: 3.441

9.  Halophilic vibrios from human tissue infections on the pacific coast of Australia.

Authors:  H K Ghosh; T E Bowen
Journal:  Pathology       Date:  1980-07       Impact factor: 5.306

10.  Variations of Bacteroides fragilis with in vitro passage: presence of an outer membrane-associated glycan and loss of capsular antigen.

Authors:  D L Kasper; A B Onderdonk; B G Reinap; A A Linberg
Journal:  J Infect Dis       Date:  1980-11       Impact factor: 5.226

View more
  25 in total

1.  Differential expression of Vibrio vulnificus capsular polysaccharide.

Authors:  A C Wright; J L Powell; M K Tanner; L A Ensor; A B Karpas; J G Morris; M B Sztein
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Monoclonal antibodies against Vibrio vulnificus RtxA1 elicit protective immunity through distinct mechanisms.

Authors:  Tae Hee Lee; Sun-Shin Cha; Chang-Seop Lee; Joon Haeng Rhee; Kyung Min Chung
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

3.  Correlation between virulence and colony morphology in Vibrio vulnificus.

Authors:  L M Simpson; V K White; S F Zane; J D Oliver
Journal:  Infect Immun       Date:  1987-01       Impact factor: 3.441

4.  Pulsed-field gel electrophoresis and ribotype profiles of clinical and environmental Vibrio vulnificus isolates.

Authors:  M L Tamplin; J K Jackson; C Buchrieser; R L Murphree; K M Portier; V Gangar; L G Miller; C W Kaspar
Journal:  Appl Environ Microbiol       Date:  1996-10       Impact factor: 4.792

5.  An epimerase gene essential for capsule synthesis in Vibrio vulnificus.

Authors:  A B Zuppardo; R J Siebeling
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

6.  Detection of anti-Vibrio vulnificus cytolysin antibodies in sera from mice and a human surviving V. vulnificus disease.

Authors:  L D Gray; A S Kreger
Journal:  Infect Immun       Date:  1986-03       Impact factor: 3.441

7.  In vivo resuscitation, and virulence towards mice, of viable but nonculturable cells of Vibrio vulnificus.

Authors:  J D Oliver; R Bockian
Journal:  Appl Environ Microbiol       Date:  1995-07       Impact factor: 4.792

8.  The extracellular cytolysin of Vibrio vulnificus: inactivation and relationship to virulence in mice.

Authors:  A C Wright; J G Morris
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

9.  Intraspecific Differentiation of Vibrio vulnificus Biotypes by Amplified Fragment Length Polymorphism and Ribotyping.

Authors:  C R Arias; L Verdonck; J Swings; E Garay; R Aznar
Journal:  Appl Environ Microbiol       Date:  1997-07       Impact factor: 4.792

10.  Identification of Vibrio vulnificus O serovars with antilipopolysaccharide monoclonal antibody.

Authors:  S J Martin; R J Siebeling
Journal:  J Clin Microbiol       Date:  1991-08       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.